



NDA 21-081/S-005

Aventis Pharmaceuticals Inc.  
Attention: Mr. Michael Lutz  
Director and Regulatory Liaison  
P.O. Box 6890  
200 Crossing Boulevard  
Bridgewater, NJ 08807-0890

Dear Mr. Lutz:

Please refer to your supplemental new drug application dated June 28, 2002, received July 1, 2002, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Lantus® (insulin glargine [rDNA origin] injection).

We acknowledge receipt of your submissions dated July 15, 2002, and January 22, and April 4, 16, and 30, 2003.

This supplemental new drug application provides for the change of dosing schedule for Lantus from once daily at bedtime to flexible daily dosing. Lantus (insulin glargine [rDNA origin] injection) is indicated for once daily subcutaneous administration in the treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia.

We completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text and with the minor editorial revisions indicated in the enclosed labeling.

The final printed labeling (FPL) must be identical, and include the minor editorial revisions indicated, to the enclosed labeling (text for the package insert, text for the patient package insert). These revisions are terms of the approval of this application.

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 21-081/S-005." Approval of this submission by FDA is not required before the labeling is used.

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to this division and two copies of both the promotional materials and the package inserts directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42  
Food and Drug Administration  
5600 Fishers Lane  
Rockville, MD 20857

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2  
FDA  
5600 Fishers Lane  
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Julie Rhee, Regulatory Project Manager, at (301) 827-6424.

Sincerely,

{See appended electronic signature page}

David G. Orloff, M.D.  
Director  
Division of Metabolic  
and Endocrine Drug Products, HFD-510  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research

Enclosure: Final Draft Physician and Patient Insert

-----  
**This is a representation of an electronic record that was signed electronically and  
this page is the manifestation of the electronic signature.**  
-----

/s/

-----  
David Orloff  
5/1/03 04:17:18 PM